CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 45 enrolled
Drug / intervention
DMAB Discontinuation and Switchingdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04177940
NCT04177940Phase 4Completed
CompareCT.gov

Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study

University of Alabama at Birmingham·interventional·Posted Nov 26, 2019·Updated Apr 23, 2026

In Brief

A Phase 4 clinical trial evaluating DMAB Discontinuation and Switching for Osteoporosis. Completed, enrolled 45 participants across 1 site.

Detailed Summary

Investigators will test the hypothesis that an increase in bone turnover markers (e.g. carboxy-terminal collagen crosslinks (CTX) and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to "late" zoledronic acid (9 months after last denosumab dose) compared to participants randomized to "early" zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesUnited States
CollaboratorsMaastricht University, Vrije Universiteit Brussel, Amgen

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedNov 26, 2019
Enrollment StartAug 17, 2020
Primary CompletionJul 22, 2024
Study CompletionJan 14, 2025
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 6.6 years ago

Interventions

DMAB Discontinuation and Switchingdrug

Investigators will test the hypothesis that an increase in bone turnover markers (e.g. CTX and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to "late" zoledronic acid (9 months after last denosumab dose) compared to participants randomized to "early" zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose